Claims for Patent: 6,464,998

Summary for Patent: 6,464,998

Title:	Composition for the in vivo production of therapeutic products
Abstract:	The present invention provides cell compositions for in vivo implantation, and designed for the sustained and controlled delivery of therapeutic substances.
Inventor(s):	Beuzard; Yves (Paris, FR), Danos; Olivier (Garches, FR), Descamps; Vincent (Marly le Roi, FR), Heard; Jean-Michel (Paris, FR), Moullier; Philippe (Meudon, FR), Naffakh; Nadia (Malakoff, FR), Perricaudet; Michel (Ecrosnes, FR), Vainchenker; William (Paris, FR)
Assignee:	Aventis Pharma S.A. (Antony, FR)
Application Number:	08/649,696
Patent Claims:	1. A composition for transplantation in vivo comprising proliferating cells, a gelling agent, and a support to which said cell are anchored, wherein said cells comprise a replication defective recombinant adenovirus comprising at least one functional adenoviral gene and a heterologous DNA sequence coding for a therapeutic product, whereby the heterologous DNA sequence is expressed and the product is produced. 2. The composition according to claim 1, wherein said cells are selected from the group consisting of fibroblasts, endothelial cells, epithelial cells, glial cells, hepatocytes, keratinocytes and myoblasts. 3. The composition according to claim 2, wherein said cells are fibroblasts. 4. The composition according to claim 1, wherein the cells are autologous with respect to an intended patient. 5. The composition according to claim 1, wherein the adenovirus is an adenovirus of human origin, canine origin, or an adenovirus comprising regions originating from a human adenovirus and a canine adenovirus. 6. The composition according to claim 5, wherein the adenovirus is selected from the group consisting of Ad2, Ad5 and CAV2. 7. The composition according to claim 1, wherein the therapeutic product is selected from the group consisting of peptides, polypeptides and proteins. 8. The composition according to claim 7, wherein the heterologous DNA sequence comprises signals enabling the therapeutic product to be produced and secreted. 9. The composition according to claim 7, wherein the therapeutic product is selected from the group consisting of enzymes, blood derivatives, insulin, variants of insulin, lymphokines, growth factors, apolipoproteins and antigenic polypeptides for the production of vaccines. 10. The composition according to claim 9, wherein said enzymes are selected from the group consisting of superoxide dismutase, catalase, amylases, lipases, amidases, and chymosin. 11. The composition according to claim 9, wherein said blood derivatives are selected from the group consisting of serum albumin, alpha-globin, beta-globin, factor VII, factor VIII, factor IX, von Willebrand factor, fibronectin and alpha.sub.1 -antitrypsin. 12. The composition according to claim 9, wherein said lymphokines are selected from the group consisting of the interleukins, interferons, colony stimulating factors, TNF, and TRF. 13. The composition according to claim 12, wherein said colony stimulating factors are selected from the group consisting of G-CSF, GM-CSF, M-CSF, and SCF. 14. The composition according to claim 9, wherein said growth factors are selected from the group consisting of growth hormone, erythropoietin, parathyroid hormone, FGF, EGF, PDGF, TGF, BNDF, NGF, and CNTF. 15. The composition according to claim 9, wherein said antigenic polypeptides are selected from the group consisting of antigens from hepatitis virus, cytomegalovirus, Epstein-Barr virus, and herpes virus. 16. The composition according to claim 1, wherein the gelling agent is selected from the group consisting of collagen, gelatin, glycosaminoglycans, fibronectin and lectins. 17. The composition according to claim 1, wherein the support is a solid, non-toxic and biocompatible support. 18. The composition according to claim 17, wherein the support is a biological support. 19. The composition according to claim 17, wherein the support is selected from the group consisting of crosslinked collagen, bone powder, carbohydrate-based polymers and limestone-based supports. 20. The composition according to claim 17, wherein the support is selected from polytetrafluoroethylene fibres. 21. A process for preparing the composition according to claim 1 comprising: a) removing a tissue sample from a body, b) isolating and culturing desired cells from said tissue sample, c) infecting the cultured cells with a replication defective recombinant adenovirus comprising at least one functional adenoviral gene and a heterologous DNA sequence coding for a therapeutic product, whereby the heterologous DNA sequence is expressed and the product is produced, d) incubating the infected cells with a medium containing a gelling agent thereby forming a mixture, e) depositing the mixture on a support, f) incubating the mixture under conditions permitting gelation of the gelling agent and anchorage of the cells to the support, and g) recovering the composition obtained in step (f). 22. The process according to claim 21, wherein the support in step e) is coated with the gelling agent. 23. The composition according to claim 1, comprising between 10.sup.5 and 10.sup.10 cells. 24. The composition according to claim 1, comprising between 10.sup.5 and 10.sup.8 cells. 25. The composition according to claim 1, wherein the heterologous DNA sequence comprises a signal sequence.

Details for Patent 6,464,998

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2013-11-23